证券代码：300314 证券简称：戴维医疗 公告编号：2025-063 宁波戴维医疗器械股份有限公司 关于召开 2025 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年第一次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》等法律、行政法规、部门 规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 11 月 03 日 14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 03 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投票的具体时间为 2025 年 11 月 03 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：202 ...

证券代码：300314 证券简称：戴维医疗 公告编号：2025-053 宁波戴维医疗器械股份有限公司 第五届监事会第十四次会议决议的公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、会议召开情况 宁波戴维医疗器械股份有限公司（以下简称"公司"）第五届监事会第 十四次会议于 2025 年 10 月 17 日在公司会议室以现场表决的方式召开。本 次会议于 2025 年 10 月 10 日以专人送达形式通知了全体监事。本次会议应 参与表决的监事 3 名，实际参与表决的监事 3 名，会议由监事会主席陈红主 持。本次会议的通知、召开以及参会监事人数均符合相关法律、法规、规则 及《公司章程》的有关规定。 二、会议审议情况 经与会监事认真审议，本次会议以记名投票表决方式表决通过如下决议： 根据《公司法》、中国证监会《关于新<公司法>配套制度规则实施相关 过渡期安排》《上市公司章程指引》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运 作》等相关法律法规、规范性文件的规定，结合公司实际情况，公司将不再 设置监事会 ...

证券代码：300314 证券简称：戴维医疗 公告编号：2025-052 宁波戴维医疗器械股份有限公司 第五届董事会第十四次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）第五届董事会 第十四次会议于2025年10月17日上午在公司会议室以现场表决的方式召 开。应参加表决董事9人，实际参加表决董事9人，符合《公司法》和《公 司章程》等相关法律法规的有关规定。本次董事会会议通知已于2025年10 月10日以专人送达、电话方式通知全体董事。董事长陈再宏先生召集和主 持了本次会议，公司监事、高管列席了会议。 二、会议审议情况 经与会董事认真审议，本次会议以记名投票的表决方式表决通过了以 下决议： 1、审议通过《关于公司董事会换届选举暨提名第六届董事会非独立 董事候选人的议案》 鉴于公司第五届董事会任期即将届满，根据《公司法》《深圳证券交 易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2 号——创业板上市公司规范运作》等法律法规、规范性文件及《公司章程》 的有关规定，经公司董事会提名委员会资 ...

证券日报网讯 10月16日晚间，戴维医疗发布公告称，宁波戴维医疗器械股份有限公司（以下简称"公 司"）于近日收到宁波市市场监督管理局核发的1项《第一类医疗器械备案编号告知书》，产品名称：心 电导联线。 （编辑 楚丽君） ...

格隆汇10月16日丨戴维医疗(300314.SZ)公布，近日收到宁波市市场监督管理局核发的1项《第一类医疗 器械备案编号告知书》，产品名称：心电导联线。以上产品备案凭证的取得，有利于丰富公司产品线， 进一步提高公司的核心竞争力，对公司未来的经营成果将产生积极影响。 ...

Core Viewpoint - David Medical (300314.SZ) has received a Class I medical device registration number notification from the Ningbo Market Supervision Administration for its product: ECG lead wires [1] Group 1 - The company has been granted regulatory approval for its ECG lead wires, indicating compliance with medical device regulations [1]

Core Viewpoint - David Medical (300314.SZ) has received a Class I medical device registration number notification from the Ningbo Market Supervision Administration for its ECG lead wires [1] Company Summary - The product involved in the notification is ECG lead wires, which are essential components in cardiac monitoring and diagnostics [1]

证券代码：300314 证券简称：戴维医疗 公告编号：2025-051 宁波戴维医疗器械股份有限公司 关于获得第一类医疗器械备案凭证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、情况概述 宁波戴维医疗器械股份有限公司（以下简称"公司"）于近日收到 宁波市市场监督管理局核发的1项《第一类医疗器械备案编号告知书》， 具体情况如下： | 产品名称 | 心电导联线 | | --- | --- | | 备案编号 | 浙甬械备20250277 | | 备案人名称 | 宁波戴维医疗器械股份有限公司 | | 备案人统一社会信 | 91330200610257495J | | 用代码 | | | 备案人住所 | 浙江省宁波市象山县石浦科技园区科苑路2号 | | 生产地址 | 浙江省宁波市象山县石浦科技园区科苑路2号 | | | DL-05-010、DL-03-020（A）、DL-03-020（B）、DL-05-020 | | | （A）、DL-05-020（B）、DL-05-110、DL-03-120（A）、 | | 型号/规格 | DL-03-120（B）、DL ...

Core Insights - David Medical announced that its wholly-owned subsidiary, Ningbo Weierkaidi Medical Equipment Co., Ltd., has received a medical device registration certificate from the Zhejiang Provincial Drug Administration for a portable electronic endoscope image processor [1] Group 1 - The product is a portable electronic endoscope image processor [1]

Group 1 - Harbin Air Conditioning plans to transfer 40% equity of its subsidiary, Harbin Fushanchuan Biotechnology Development Co., Ltd. The subsidiary reported a net profit of -16.0963 million yuan for 2024, which is 218.83% of the previous year's net profit absolute value [1] - Xinhua Insurance expects a net profit of 29.986 billion to 34.122 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 45% to 65% [1][2] - Gansu Energy anticipates a net profit of 1.55 billion to 1.6 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 11.86% to 15.47% [2][3] Group 2 - Dongfang Tower forecasts a net profit of 750 million to 900 million yuan for the first three quarters of 2025, indicating a year-on-year growth of 60.83% to 93% [4] - Meili Eco announced that its subsidiary won a bid for an EPC project worth 2.375 billion yuan [6] - Bohai Chemical's wholly-owned subsidiary will undergo routine maintenance for its 600,000 tons/year PDH unit, expected to last about 30 days [8] Group 3 - Qin Port Co. reported a total throughput of 317.02 million tons for the first nine months of 2025, a year-on-year increase of 5.56% [10] - Jianglong Shipbuilding won a bid for a 72.99 million yuan fishery enforcement vessel project, accounting for 4.22% of its 2024 audited revenue [11] - Longyuan Technology expects a net profit of 35 million to 40 million yuan for the first three quarters of 2025, representing a year-on-year increase of 50.11% to 71.55% [12] Group 4 - Naipu Mining anticipates a net profit of 61 million to 66 million yuan for the first three quarters of 2025, reflecting a year-on-year decline of 45.16% to 49.32% [14] - Jinggong Steel Structure reported a cumulative contract amount of 17.98 billion yuan for the first nine months of 2025, a year-on-year increase of 4.8% [15][16] - Shenzhen Gas reported a net profit of 918 million yuan for the first three quarters of 2025, a year-on-year decrease of 13.08% [17] Group 5 - Yabao Pharmaceutical's subsidiary received a drug registration certificate for a new diabetes medication [18] - Shaanxi Coal's coal production in September was 14.56 million tons, a year-on-year increase of 5.34% [20] - Sifang New Materials reported a 15.94% year-on-year decline in concrete production for the first three quarters [22] Group 6 - Nanjing Foods reported a consolidated revenue of 276 million yuan in September, a slight increase of 0.0016% year-on-year [23] - Pulaike received a new veterinary drug registration certificate for a flea and tick treatment [24] - Zhucheng Technology received a cash dividend of 15 million yuan from its subsidiary [25] Group 7 - David Medical's subsidiary received a medical device registration certificate for a portable electronic endoscope image processor [26] - Zhongtong Bus reported a 36.88% year-on-year increase in sales in September, totaling 1,106 units [27] - Xiantan Co. reported a 11.95% year-on-year increase in chicken sales revenue in September [28] Group 8 - Bojun Technology expects a net profit of 552 million to 662 million yuan for the first three quarters of 2025, a year-on-year increase of 50% to 80% [30] - Haishi Pharmaceutical's innovative pain relief drug clinical trial application has been accepted [31] - Lingxiao Pump Industry used 80 million yuan of idle funds to purchase financial products [32] Group 9 - Qiangda Circuit's subsidiary completed business registration changes to expand its operational scope [33] - *ST Tianyu's controlling shareholder applied for bankruptcy liquidation due to severe financial difficulties [34] - Baolidi's shareholder plans to reduce holdings by up to 1 million shares [36] Group 10 - Zijin Mining completed the acquisition of Kazakhstan's Raygorodok gold mine, controlling 100% of its rights [44] - Zhonggang Luoyang's indirect controlling shareholder completed a capital increase, raising registered capital from approximately 26.666 billion yuan to 44.824 billion yuan [46] - Jinyu Jidong's director resigned due to work adjustments [47]